Cathie Wood’s ARK Invest Sells Over 175,000 Shares of Roche
One of Cathie Wood's Ark Invest funds sold almost 178,000 shares of Roche on August 19.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 175,000 shares of Roche Holding AG (NYSEARCA: RHHBY) on Thursday, as the share price of this fund traded down nearly 2% in the day’s session. However, the fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 177,900 shares of Roche. At Thursday’s closing price, this would have valued this sale at roughly $9.0 million. This is only a small fraction of the total holdings. This fund is up 26% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | 1833HK | Ping An Healthcare and Technology | 524,000 |
| ARKG | RHHBY | Roche | 177,900 |
| ARKG | SRPT | Sarepta Therapeutics | 17,408 |
| ARKG | PSTI | Pluristem Therapeutics | 7,224 |
| ARKK | MCRB | Seres Therapeutics | 10,974 |
| ARKK | NSTG | Nanostring Technologies | 47,361 |
| ARKK | DOCU | Docsign | 51,743 |
| ARKK | SQ | Square | 41,400 |
| ARKQ | XONE | Exone | 59,797 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=937859][wallst_email_signup]
Contact [email protected] for any questions or corrections.







